ATHE - Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund | Benzinga
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government's Research and Development Tax Incentive (R&DTI) Scheme.
The cash refund relates to the cost of eligible research and development activities conducted during the financial year ended 30 June 2023, and represents the amount disclosed in the company's audited financial statements. These funds will be used to further Alterity's Phase 2 clinical trials in MSA, ATH434-201 and ATH434-202, along with planning for a potential Phase 3 clinical trial in MSA, ...